Stock Research for AERI

AERI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AERI Stock Chart & Research Data

The AERI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AERI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AERI Due diligence Resources & Stock Charts

The AERI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AERI Detailed Price Forecast - CNN Money CNN View AERI Detailed Summary - Google Finance
Yahoo View AERI Detailed Summary - Yahoo! Finance Zacks View AERI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AERI Trends & Analysis - Trade-Ideas Barrons View AERI Major Holders - Barrons
NASDAQ View AERI Call Transcripts - NASDAQ Seeking View AERI Breaking News & Analysis - Seeking Alpha
Spotlight View AERI Annual Report - CompanySpotlight.com OTC Report View AERI OTC Short Report - OTCShortReport.com
TradeKing View AERI Fundamentals - TradeKing Charts View AERI SEC Filings - Bar Chart
WSJ View Historical Prices for AERI - The WSJ Morningstar View Performance/Total Return for AERI - Morningstar
MarketWatch View the Analyst Estimates for AERI - MarketWatch CNBC View the Earnings History for AERI - CNBC
StockMarketWatch View the AERI Earnings - StockMarketWatch MacroAxis View AERI Buy or Sell Recommendations - MacroAxis
Bullish View the AERI Bullish Patterns - American Bulls Short Pains View AERI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AERI Stock Mentions - StockTwits PennyStocks View AERI Stock Mentions - PennyStockTweets
Twitter View AERI Stock Mentions - Twitter Invest Hub View AERI Investment Forum News - Investor Hub
Yahoo View AERI Stock Mentions - Yahoo! Message Board Seeking Alpha View AERI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AERI - SECform4.com Insider Cow View Insider Transactions for AERI - Insider Cow
CNBC View AERI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AERI - OTC Markets
Yahoo View Insider Transactions for AERI - Yahoo! Finance NASDAQ View Institutional Holdings for AERI - NASDAQ


Stock Charts

FinViz View AERI Stock Insight & Charts - FinViz.com StockCharts View AERI Investment Charts - StockCharts.com
BarChart View AERI Stock Overview & Charts - BarChart Trading View View AERI User Generated Charts - Trading View




Latest Financial News for AERI


See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
Posted on Wednesday January 09, 2019

# Aerie Pharmaceuticals Inc ### NASDAQ NMS:AERI View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 19. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding AERI is favorable, with net inflows of $5.38 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.


Aerie's Rhopressa Succeeds in Study on Japanese Patients
Posted on Monday January 07, 2019

Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.


Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan
Posted on Friday January 04, 2019

Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye today announced the topline results of its pilot Phase 2 study of netarsudil ophthalmic solution in a Japanese-American population. The study was designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support the potential regulatory submission of netarsudil ophthalmic solution in Japan.


Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access
Posted on Wednesday January 02, 2019

Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Ami Bavishi as Director, Investor Relations, reporting to Richard Rubino, Aerie’s Chief Financial Officer. Ms. Bavishi will drive all of Aerie’s investor relations activities, and joins Aerie from Burns McClellan, a public relations and investor relations firm with which Aerie will maintain an ongoing relationship.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.